Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on January 9, 2017. The filing serves as a Regulation FD disclosure regarding the Company's participation in the 35th Annual J.P. Morgan Healthcare Conference held in San Francisco, California, from January 9-13, 2017.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a presentation event and does not contain financial statements or performance data.
Material Changes
No material changes to financial position or operations are reported in this document. The filing solely announces the availability of presentation materials regarding the Company's antiviral therapies.
Guidance, Outlook, and Risks
The Company presented information on its antiviral therapies to investors. The presentation materials are included as Exhibit 99.1 and are available on the Company's website under the "News" and "Presentations" sections. No specific financial guidance, outlook, or new risk factors are detailed within the text of this 8-K.
Key Facts for Investor Verification
- Verify the content of the presentation materials (Exhibit 99.1) for details on antiviral therapy progress.
- Confirm the date and location of the J.P. Morgan Healthcare Conference presentation (January 9-13, 2017, San Francisco).
- Note that this filing contains no financial data; refer to recent 10-K or 10-Q filings for financial metrics.